glp 1 agonists for type 2 diabetes Targeting GLP-1, GIP & GCG in Obesity and Research GLP1 Receptor Agonists vs SGLT2-I

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made

Injection site reactions occur in 14% of users, typically presenting as mild redness, itching, or temporary discomfort at the injection location

*Benefits as shown are reported in ingredient-specific studies

MOTS-c Strength: 10 mg Mitochondrial-derived peptide A performance and energy-oriented peptide option frequently associated with metabolic resilience support

In a post hoc analysis of the SURPASS-1 trial involving patients with T2DM, the percentage increase in adiponectin levels from baseline ranged from 16% to 23% with tirzepatide compared to a decrease of 0.2% with placebo at week 40 (190)